<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02193698</url>
  </required_header>
  <id_info>
    <org_study_id>G26007</org_study_id>
    <nct_id>NCT02193698</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial</brief_title>
  <official_title>Single Arm Open-label Trial to Investigate the Efficacy and Safety of Lenlidomide as a Treatment for Recurrent or Refractory Crow-Fukase (POEMS) Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiba University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiba University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the efficacy and safety of Lenalidomide as a treatment for recurrent
      or refractory POEMS (Crow-Fukase) syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study investigates the efficacy and safety of Lenalidomide as a treatment for recurrent
      /refractory POEMS (Crow-Fukase) syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction rate of serum VEGF</measure>
    <time_frame>after 24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>POEMS Syndrome</condition>
  <arm_group>
    <arm_group_label>Lenalidomide+Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle1 : Lenalidomide 15mg/day (day 1-21) Cycle2-6 : Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide+Dexamethasone</intervention_name>
    <description>Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)</description>
    <arm_group_label>Lenalidomide+Dexamethasone</arm_group_label>
    <other_name>Lebramide+Decadoron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with Crow-Fukase syndrome (confirmed by diagnostic criteria.)

          2. Recurrent or refractory Crow-Fukase syndrome.

          3. Patients without severe liver or renal dysfunction.

          4. Patients without severe neutropenia or thrombocytopenia.

          5. Patients without clinically problematic ECG findings

          6. Negative on the pregnacy test on the day 1 of cycle 1.

          7. Patients who can undertake prevention of pregnancy, if necessary.

          8. Patients with written informed consent.

          9. Patients who are capable of ambulatory hospital visits every 4 weeks.

         10. Patients with informed consent to the registration and rules of RevMateÂ®.

        Exclusion Criteria:

          1. Patients who have been administered, bortezomib, lenalidomide, melpharan within 4
             weeks prior to the registration.

          2. Patients who have been on steroid treatment (more than 10mg/day in predonine) within 2
             weeks prior to the registration.

          3. Patients who have been administered bevacizumab within 12 weeks prior to the
             registration.

          4. Patients who could worsen acutely during the clinical trial period.

          5. Patients with severe complicaitons ( cardiac failure, renal failure liver failure,
             bleeding enterogastric ulcer, ileus, poorly controlled diabetes.

          6. Patients with malignancies.

          7. Female patients who are pregnant or desire childbearing. Males who desire fertility.

          8. Patients who allergic to lenalidomide or dexamethasone.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonoko Misawa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chiba University, Department of Neurology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chiba University Graduate School of Medicine Department of neurology</name>
      <address>
        <city>Chiba</city>
        <zip>260-8760</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2014</study_first_submitted>
  <study_first_submitted_qc>July 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2014</study_first_posted>
  <last_update_submitted>July 27, 2016</last_update_submitted>
  <last_update_submitted_qc>July 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chiba University</investigator_affiliation>
    <investigator_full_name>Sonoko Misawa</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>POEMS syndrome</keyword>
  <keyword>lenalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>POEMS Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

